IL1RL1
Interleukin-1 receptor-like 1
As of the edition of 20 October 2026, IL1RL1 (interleukin-1 receptor-like 1, UniProt Q01638) has 2 drugs tested at it and 4 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q01638
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Lungs and airways; Immune system; Inherited and neonatal; Skin and connective tissue
- Registered trials of its drugs
- 13
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Astegolimab | Active | Phase 3 | none listed |
| Melrilimab | Went quiet | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Undetermined | 2 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| GSK | Route A |
| Johnson & Johnson | Route A |
The other 2 companies at IL1RL1
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at IL1RL1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.